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Background: It has been hypothesized that incomplete endothelialization and delayed vascular healing may trig-
ger stent thrombosis events after drug-eluting stent (DES) implantation. We aimed to demonstrate non-
inferiority in terms of neointimal coverage of novel Cre8 DES at 3 months, compared to Vision/Multilink8 Bare
Metal Stent (BMS) at 1 month.
Methods: The ranDomizEd coMparisOn betweeN novel Cre8 DES and BMS to assess neoinTimal coveRAge by OCT
Evaluation (DEMONSTRATE) was a multicenter, randomized, parallel group study. Thirty-eight patients under-
going angioplasty of de-novo coronary lesion were randomized to Cre8 (19) or Vision/Multilink8 (19) stent
placement at 6 OCT-experienced centers. Primary end-point was the Ratio of Uncovered to Total Stent Struts
Per Cross Section (RUTTS) score of b30%, determined by OCT at 3 and 1 months for Cre8 and Vision/Multilink8,
respectively. Percentage of uncovered/malapposed stent struts, neointimal growth and thickness were themain
secondary end-points.
Results: The primary end-point of RUTTS score b30% occurred in 99.8% (899/901) of Cre8 struts and in 99.6%
(1116/1121) of Vision/Multilink8 struts (difference 0.2, CI 95%−0.2 to 0.6, p for noninferiority b0.001). The per-
centage of uncovered/malapposed struts was comparable (0.36 ± 0.64 vs. 0.12 ± 0.24, p = 0.145) in the two
study groups, while both neointimal percentage area (8.46 ± 5.29 vs. 19.84 ± 15.93, p b 0.001) and thickness
(0.07 ± 0.04 vs. 0.16 ± 0.12, p b 0.001) were signiﬁcantly reduced by Cre8 stent.
Conclusions: The Cre8DES at 3 monthshas comparable strut coverage toVision/Multilink8BMS at 1 monthwhile
preserving a greater efﬁcacy in neo-intima formation reduction. Further studies to assess clinical implication of
these Cre8 characteristics are warranted.© 2014 Published by Elsevier Ireland Ltd.1. Introduction
Although drug-eluting stents (DES) remarkably reduce the rate of
in-stent angiographic restenosis and subsequent target lesion revascu-
larization (TLR) compared with bare-metal stents (BMS) [1–3],
concerns about the long term safety of DES exist [4,5]. In fact, the
drug-induced delay in vascular healing results in unpredictable andnal Cardiology, San Giovanni-
e, Italy.
.incomplete endothelialization possibly leading to an increased risk of
late and very late stent thrombosis. Thus, while in case of BMS implan-
tation the guidelines recommend only one month of dual antiplatelet
therapy (DAPT) [6], there is a paucity and controversy of evidence re-
garding the optimal duration of DAPT [7,8] with DES; moreover, it is
also unclear whether DAPT duration should be the same for the differ-
ent DES brands.
In this context, frequency domain optical coherence tomography
(FD-OCT) with its innovative high-resolution imaging system allows
in vivo characterization of intraluminal and endothelial structures [9,
10]; in particular, it permits semi-automated accurate insights regarding
905F. Prati et al. / International Journal of Cardiology 176 (2014) 904–909stent apposition, strut coverage and neointimal growth. Indeed, previ-
ous studies demonstrated an association between lack of neointimal
strut coverage and thrombus formation, with the greatest thrombotic
risk for uneven healed DES (as indicated by the number of uncovered
struts per cross section) [11–13].
Recently a new DES generation, the Cre8 (CID, Saluggia, Italy), has
entered the market. Its Cobalt–Chromium polymer free platform with
abluminal reservoir technology for drug release and the iCarboﬁlm
(commercially named Bio Inducer Surface — BIS) coating assure high
biocompatibility/thromboresistance and promise accelerated strut en-
dothelialization after implantation [14,15]. Thus, the purpose of this
study is to demonstrate the noninferiority in terms of vessel healing
and strut coverage evaluated with OCT of the novel DES Cre8 at
3 months as compared to a standard renowned BMS at 1 month.
2. Methods
2.1. Study design and end-points
The ranDomizEd coMparisOn betweeN a DES and a BMS to assess neoinTimal coveR-
Age by OCT Evaluation (DEMONSTRATE) was a multicenter, prospective, randomized,
parallel group study designed to investigate with FD-OCT the vascular healing pattern of
Cre8 DES, compared with a BMS having a similar 80 μm strut thickness, the Vision/
Multilink8.
All subjects undergoing coronary angioplasty of de novo lesion in native coronary
arteries assessable with OCT were eligible for the study. Inclusion/exclusion criteria
adopted in this study are reported in Appendix 1. At the end of diagnostic exam, all
enrolled patients were randomized (1:1 ratio) to receive Cre8 or Vision/Multilink8 stent
on the basis of a central randomization system; random assignment was stratiﬁed for
acute coronary syndrome to prevent imbalance between groups. By protocol all patients
underwent OCT-guided angioplasty and received scheduled clinical examination at 1, 3
and 12 months after the procedure in order to verify clinical status and occurrence of
any adverse event. In addition, patients in Vision/Multilink8 and Cre8 arms underwent
angiographic and OCT evaluations at 1 and 3 months after the procedure, respectively.
For BMS the choice of an OCT follow-up length of 1 month was based on the current
standard guidelines for DAT duration, while for Cre8 the 3 month OCT follow-up length
was based on in vivo randomized study data, showing a completed drug-elution within
3 months from implant [15].
The study protocol received ethical committee approval and all patients provided
written informed consent to the procedure. The DEMONSTRATE trial is registered with
ClinicalTrials.gov, NCT01543373.
As primary objective of the study we appraised the Ratio of Uncovered to Total Stent
Struts Per Cross Section (RUTTS) score of b30%, determined by OCT at 1 or 3 months,
according to the randomization group. Secondary objectives were percentage of uncov-
ered and malapposed stent struts, neointimal growth and neointimal thickness, minimal
lumen diameter, restenosis percentage and late lumen loss at the pre-speciﬁed OCT
follow-ups. As clinical endpoint we also assessed the composite rate of cardiac death,
target vessel-relatedmyocardial infarction (MI) and clinically driven target lesion revascu-
larization (TLR) at 1 and 3 months from the index procedure. The end-points were
analyzed on the basis of an intention to treat principle by a blinded central independent
clinical-event committee.
2.1.1. Core laboratory analyses
All OCT and Quantitative Coronary Analyses (QCA) were performed by an indepen-
dent Core laboratory (Rome Heart Research s.r.l.) with speciﬁc expertise in intravascular
imaging. All assessments were performed off-line by personnel blinded to procedural
data and clinical outcome.
In particular, lesion and vessel parameters were obtained by means of QCAmeasure-
ments using an automated edgedetection algorithm(Medis 7 Cardiovascular angiography
Analysis System II, The Netherlands). Similarly, all OCT frames were digitally stored and
analyzed using an off-line software (LightLab Consolle, Westford, Massachusetts, USA)
applying a 0.20-mm intervals, on all available frames. Assessment of strut tissue coverage,
malapposition and neointimal thickness was done at stent level (per-stent analysis). The
count of struts with uncoverage/malapposition and cross-sections with RUTTS score
b30% was done in each single stent and expressed as the average of measurements calcu-
lated for each stent. Stent with suboptimal strut visualization (i.e. inability of OCT to
address all stent struts in a speciﬁc cross-section) in more than 10% of total stent struts
was excluded from ﬁnal analysis.
2.2. Population and procedures
Patient enrolment was carried out in a prospective and sequential way, so that all
consecutive patient candidates to percutaneous revascularization angioplasty could theo-
retically participate into the trial (Fig. 1). Patient preparation and percutaneous access
were performed according to the standard local hospital practice. All patients were pre-
treated with acetylsalicylic acid plus loading dose of thienopyridine while procedural
anticoagulation was achieved with unfractionated heparin maintaining an activatedclotting time of N300 s or 200 s in case of GP IIa/IIIb inhibitors use. Standardized
angiographic and OCT acquisitions were performed in order to obtain a more accurate
evaluation of the QCA and intravascular parameters. Predilation of target lesion was
mandatory and stents were selected in order to exceed the lesion length by 5 mm
(2.5 mm for each stent side). Post-dilation with shorter non-compliant balloon was
performed when needed, to obtain a residual stenosis b30% with TIMI ﬂow III and a
stent diameter/reference vessel diameter ratio ≥ 1.1. By protocol, only one study stent
could be used per lesion. However, in case of documentedmajor dissection and/or compli-
cation (e.g. lesion mismatch) additional stent(s) were allowed using the same stent type,
according to the randomization protocol. After the procedure, all antithrombotic agents
were discontinued according to local hospital practice depending on stent implanted.
2.3. Data collection and deﬁnitions
By design, speciﬁc database and explicit deﬁnitions for outcomes were adopted. Data
about clinical follow-up were obtained by direct visit or contact with referring physician.
In case of any adverse clinical occurrence documentation was collected and analyzed by
the central clinical-event committee.
Strut coverage was deﬁned as a measured tissue thickness N0 μm on the luminal
surface of the strut [10,11]. Strut malapposition was deﬁned as a distance ≥80 μm from
the inner edge of the strut to the vessel wall [10,11].
Cardiac death was deﬁned as any death due to cardiac cause, procedure-related
deaths, and death of unknown cause. MI was deﬁned as new ischemic symptoms lasting
N20 min and new or recurrent ST-segment elevation or depression N1 mm in at least
2 contiguous leads, associated with an increase of the cardiac biomarker [16]. Clinically
indicated TLR was deﬁned as any revascularization procedure performed because of
angiographic restenosis/thrombosis N70% at the site of the culprit lesion or restenosis
N50% (core lab QCA assessment) associatedwith clinical or objective evidence of inducible
myocardial ischemia. Stent thrombosis was classiﬁed utilizing the Academic Research
Consortium (ARC) deﬁnition [17].
2.4. Statistical analysis
In the DEMONSTRATE trial we hypothesized that the grade of endothelialization of
Cre8 stent at 3 months would not be inferior to Vision/Multilink8 at 1 month (BMS
with comparable strut thickness). The sample size was calculated assuming a 95% of
cross sections with a Ratio of Uncovered to Total Stent Struts Per Cross Section (RUTTS)
score of b30% in Vision/Multilink8 group after 1 month, and using an absolute delta
non-inferiority margin of 5% with a 97.5% one-sided signiﬁcance level of the risk differ-
ences. Thus, we computed that 1792 cross sections were required to have 90% power to
detect the non-inferiority of the Cre8 when compared to Vision/Multilink8, in terms of
strut coverage. Taking into account a cross-sectional OCT image analysis at 0.2 mm inter-
vals and assuming amean lengthof stented segment of 20mmper patient, weﬁgured that
at least 18 patients (9 per arm) should be enrolled to obtain the 1792 cross sections
required. In order to have a more sample representative of the overall population and to
minimize bias due to randomization, the enrolment was extended to a total of 40 patients
(20 per arm). Analyses were conducted on intention-to-treat basis.
Datawere reported asmeans (±standard deviation) for continuous variables normal-
ly distributed, as median (±inter-quartile range) for continuous variable that failed the
normal distribution test and as counts and percentages for categorical variables. Levene's
test or Brown–Forsythe test were used for comparison according to homogeneity of
variances between groups; Student t or Mann–Whitney U test for continuous and Fisher
exact tests for bivariate analyses were computed when appropriate.
For the non-inferiority primary endpoint the conﬁdence limit of the risk difference
and a single tailed (alpha = 0.025) test was performed, while for all other comparisons
a two tailed (alpha = 0.05) test was adopted.
3. Results
The ﬁnal study population included 38 patients undergoing OCT-
guided angioplasty of de novo coronary lesion at six European high-
volume centers. Two patients (one per arm) who had a baseline OCT
assessment refused the follow-up control and were therefore excluded
from the ﬁnal analysis. Each Investigational Center enrolled aminimum
of 5 patients and the recruitment was competitive among the centers
involved.
Patients enrolled in the two study groups were similar for demo-
graphic and clinical characteristics (Table 1). Baseline angiographic
and procedural data addressed with QCA and OCT were also well
balanced. Finally, there were no differences in the rate of angiographic
complication (e.g. dissection at edge stent) and procedural success
between the two study arms (Table 2).
The primary end-point of RUTTS score b30% occurred in 99.6%
(2015/2022) of sections analyzed with no difference between the Cre8
(99.8%, 899/901) at 3-month follow-up and the Vision/Multilink8
(99.6%, 1116/1121) at 1-month follow-up (difference 0.2, CI 95%−0.2
Fig. 1. Study ﬂow chart.
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centage of uncovered stent strutswas comparable in Cre8 (1.59± 2.10)
and in Vision/Multilink8 (0.86 ± 1.38, p = 0.228) groups, with noTable 1
Baseline clinical patients' characteristics.
Cre8 (19) Vision/Multilink8 (19) p
Age (years)a 69.2 (±8.6) 65.0 (±8.6) 0.1406
Male gender 84.2% (16/19) 63.2% (12/19) 0.2691
Hypertension 84.2% (16/19) 68.4% (13/19) 0.4470
Hyperlipidemia 68.4% (13/19) 47.4% (9/19) 0.3245
Smoke habit 47.4% (9/19) 57.9% (11/19) 0.7459
Family history of CAD 15.8% (3/19) 42.1% (8/19) 0.1510
Diabetes mellitus 26.3% (5/19) 15.8% (3/19) 0.6928
Prior myocardial infarction 26.3% (5/19) 36.8% (7/19) 0.7281
Prior revascularization 26.3% (5/19) 31.6% (6/19) 1.0000
Diagnosis
Silent ischemia 31.6% (6/19) 26.3% (5/19) 1.0000
Stable angina 57.9% (11/19) 47.4% (9/19) 0.7459
Unstable Angina 5.3% (1/19) 15.8% (3/19) 0.6039
NSTEMI 5.3% (1/19) 10.5% (2/19) 1.0000
NSTEMI = non ST-elevation myocardial infarction; CAD = coronary artery disease.
a Expressed as mean and standard deviation.difference also in the presence of two overlapping stents (0.00 ± 0.00
vs. 1.39 ± 2.41, p = 0.670).
Although a comparable strut malapposition rate (7.57 ± 7.78 vs.
5.63 ± 6.30, p = 0.450) was appreciated at OCT post-implantation a
signiﬁcant higher percentage was found at the 3-month follow-up in
the Cre8 arm (4.18 ± 5.09 vs. 1.21 ± 1.72, p b 0.001) conﬁned to the
non-overlapping stent segments. Nevertheless, the rate of uncovered
and malapposed stent struts did not differ between the two study
groups (0.36 ± 0.64 vs. 0.12 ± 0.24, p = 0.145). No signiﬁcant differ-
ences or inconsistent data were observed among the enrolling centers.
None of the baseline clinical characteristic (e.g. NSTEMI diagnosis) or
of the peri-procedural variables (Tables 1–2) showed a signiﬁcant cor-
relation with the primary and secondary endpoints.
Both the median neo-intimal area percentage (8.46 ± 5.29 vs.
19.84 ± 15.93, p b 0.001) and median neo-intimal thickness (0.07 ±
0.04 vs. 0.16 ± 0.12, p b 0.001) were signiﬁcantly reduced in Cre8
group when compared to Vision/Multilink8 group (Figs. 2 and 3). The
inhibition of neo-intimal formation in terms of area and thickness was
evident also in the presence of a double strut layer (14.67 ± 3.99 vs.
32.58 ± 12.86, p b 0.001 and 0.14 ± 0.03 vs. 0.19 ± 0.04, p b 0.001,
respectively).
Furthermore thin and homogenous tissue coverage was appreciated
in all cases treatedwith theCre8 (Fig. 2). Consistently theQCAminimum
Table 2
Baseline and post implantation angiographic and OCT lesions' characteristics.
Cre8 (19) Vision/Multilink8 (19) p
Target vessel
Left main trunk 0.0% (0/19) 0.0% (0/19) 1.000
Left descending artery 42.1% (8/19) 36.8% (7/19) 0.998
Left circumﬂex artery 31.6% (6/19) 31.6% (6/19) 0.727
Right coronary artery 26.3% (5/19) 31.6% (6/19) 0.998
Lesion classiﬁcation ACC/AHA
Type A 5.2% (1/19) 0 (0/19) 0.959
Type B1 47.4% (9/19) 42.1% (8/19) 0.998
Type B2 36.8% (7/19) 47.4% (9/19) 0.739
Type C 10.5% (2/19) 10.5% (2/19) 0.597
Stent implantation
No. stent per
lesion (range)a
1.3 ± .05 (1–3) 1.2 ± .04 (1,2) 0.547
Mean stent
diameter (mm)a
3.1 ± 0.4 3.0 ± 0.4 0.240
Mean stent
length (mm)a
19.3 ± 4.9 19.8 ± 6.3 0.780
Maximum inﬂation
pressure (atm)a
14.7 ± 3.7 16 ± 2.3 0.168
Basal QCA/OCT
Minimum lumen
diameter (mm)a
0.70 ± 0.38 0.74 ± 0.32 0.728
Reference vessel
diameter (mm)a
2.75 ± 0.49 2.55 ± 0.33 0.200
Diameter stenosis (%)a 73.86 ± 14.36 70.28 ± 14.33 0.447
Post intervention QCA/OCT
Minimum lumen
diameter (mm)a
2.71 ± 0.32 2.67 ± 0.48 0.764
Reference
diameter (mm)a
3.05 ± 0.40 2.91 ± 0.52 0.390
Diameter stenosis (%)a 10.90 ± 4.90 8.23 ± 3.41 0.070
Mal-apposition (%)a 7.57 ± 7.78 5.63 ± 6.30 0.450
Edge dissection 200 μ (%) 6.8% (7/19) 6.8% (7/19) 0.737
a Expressed as mean and standard deviation.
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stent late loss (0.10 ± 0.33 mm vs. 0.43 ± 0.36 mm, p b 0.001) and re-
sidual diameter stenosis (9.26 ± 4.98% vs. 19.07 ± 12.67%, p = 0.005)Table 3
Angiographic, OCT and clinical outcome at follow-up.
Cre8 (19) Vision/Multilink8 (19) p
Follow-up QCA (3 vs. 1 month)
MLD (mm) a 2.61 ± 0.34 2.24 ± 0.60 0.033
REF (mm) a 2.89 ± 0.42 2.76 ± 0.58 0.480
Late loss (mm) a 0.10 ± 0.33 0.43 ± 0.36 b0.001
Diameter stenosis (%)a 9.26 ± 4.98 19.07 ± 12.67 0.005
Follow-up OCT (3 vs. 1 month)
RUTTS
score b30% (%)
99.8 (899/901) 99.6 (1116/1121) b0.001b
Uncovered struts (%)a 1.59 ± 2.10 0.86 ± 1.38 0.228
Strut mal-apposition (%)a 4.18 ± 5.09 1.21 ± 1.72 b0.001
Uncovered and malapposed
struts (%)a
0.36 ± 0.64 0.12 ± 0.24 0.145
Neointima area (%)c 8.46 ± 5.29 19.84 ± 15.93 b0.001
Neointima thickness (mm) c 0.07 ± 0.04 0.16 ± 0.12 b0.001
Follow-up MACE (3 months)
Cardiac death (%) 0 (0/19) 0 (0/19) 1.000
Myocardial infarction (%) 0 (0/19) 0 (0/19) 1.000
Clinical TLR (%) 0 (0/19) 5.2 (1/19) 0.959
QCA = quantitative coronary angiography. OCT = optical coherence tomography.
RUTTS = Ratio of Uncovered to Total Stent Struts Per Cross Section. TLR = target lesion
revascularization.
a Expressed as mean and standard deviation.
b p for noninferiority.
c Expressed as median and interquartile range.were signiﬁcantly improved in the Cre8 stent group at the pre-speciﬁed
angiographic follow-up.
No outcome difference, in terms of cardiac death, target vessel-
related MI and clinically-driven TLR was found at the 3-month clinical
follow-up. In particular, only one TLRdue to early restenosiswas record-
ed in the Vision/Multilink8 group onemonth after the index procedure.
4. Discussion
The results of the present multi-center randomized clinical trial can
be summarized as follows: 1) the high biocompatibility of the Cre8 DES
led to a homogenous tissue coverage after 3 months, comparable to that
achievable with BMS at 1 month, opening therefore a door for possible
improvement of the long-term DES safety and for reconsideration of
DAPT duration and 2) the Cre8 DES showed an excellent neo-intima
suppression, similar to that achieved with other DES and much greater
than that obtained in the BMS group.
A recent network meta-analysis has shown as stent strut thickness,
thromboresistant properties of polymer and reduced drug load may
contribute to increase long termDES safety [18]. In particular, some sec-
ondgenerationDES seemnot to be associatedwith a signiﬁcant increase
in stent thrombosis risk over time, also when compared to BMS. Never-
theless, the effective role of single DES components (e.g. stent platform,
polymer or drug) in determining such a reassuring result remains to be
determined [19].
In this context, the novel drug-eluting Cre8 stent has an innovative
design, combining the previous demonstrated non-thrombogenic prop-
erties of the integral pure carbon coating [20–22] (BIS) with a new drug
loading technology. The Cre8 has a polymer-free Cobalt–Chromium
platform with abluminal reservoir providing controlled and directed
elution exclusively targeted to the vessel wall. The drug is Sirolimus
combined with an organic acid (Amphilimus formulation) that is an ac-
tive drug carrier assuring enhanced drug bioavailability with sustained
and homogenous distribution to the entire vessel wall. Preliminary
study showed brilliant results both for the BIS in terms of tissue cover-
age [22] and for the Amphilimus formulation in terms of neo-intima
suppression [14,15].
The present OCT study conﬁrmed the excellent in vivo stent strut
coverage of the BIS also in combination with the Sirolimus, which is a
highly effective antiproliferative agent. Indeed, patients treated with
Cre8 had no differences in terms of percentage of uncovered stent
when compared to a BMS.
Early and complete re-endothelialization represents a crucial aspect
for intracoronary devices, especially for DES. Indeed, the drug-induced
delay of vessel healing and incomplete strut coverage have been advo-
cated as the main causes of late and very late thrombosis recorded
with ﬁrst generation DES [12,13].
More importantly, the Cre8 showed that the almost complete stent
coverage is associated with a marked reduction of neo-intimal forma-
tion. Indeed, all the OCT neo-intimal growth indexes, including the inti-
mal area percentage, intimal thickness, minimum lumen diameter and
residual diameter stenosis were signiﬁcantly improved by Cre8 when
compared to Vision/Multilink8. These data conﬁrm the validity of the
innovative drug loading system of Cre8. The absence of a permanent
polymer, triggering a chronic inﬂammatory stimuli and the more com-
plete and homogenous distribution of drug assured by the Amphilimus
formulation, are probably the main determinants of these distinctive
ﬁndings.
The small but signiﬁcantly higher incidence of late malapposed
struts, found in the Cre8 group with respect to Vision/Multilink8
group, is likely the inevitable consequence of the active drug-induced
neo-intima suppression. Dissolution of thrombotic remnants between
the abluminal strut side and the vessel wall or drug-induced positive
plaque remodeling can generate empty spaces that require a marked
neointima formation to be ﬁlled up during the follow-up. Nevertheless,
the practical impact of late malapposition, frequently described with
Fig. 2. Distribution of in stent neo-intima area of Cre8 and Vision/Multilink8 at 3-month and 1-month follow-up, respectively.
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creased risk of adverse events (i.e. stent thrombosis) [12,13]. Further-
more, no difference in number of malapposed and uncovered struts
was found between the two study groups.
Thus, the Cre8 represents a promising device balancing efﬁcacy,
expressed in terms of restenosis reduction, and safety, expressed in
terms of optimal stent coverage. The latter represents the main chal-
lenge for future DES generation. Indeed, to date, there is great uncer-
tainty about long term vessel reaction to DES and the only data
available derived from meta-analyses or post-mortem studies on pa-
tients experiencing fatal adverse events. In these autoptic studies, a
tight correlation between drug efﬁcacy in neo-intima suppression and
incidence of incomplete or uneven stent re-endothelialization has
been described [12,13]. Moreover, stent polymer represents a perma-
nent target for inﬂammatory cells that can lead to a chronic inﬂamma-
tory response and inadequate vessel healing of the stented segment
[12,13]. The novel Cre8 design represents a possible solution to over-
come both these problems and to reconsider DAPT duration require-
ment after DES implantation.
Finally, the modern OCT technology offers the possibility to explore
in vivo the interplay between stents and vessel-wall reaction. In partic-
ular, the OCT resolution is able to describe with high level of accuracy
superﬁcial structures, depicting stent strut coverage andmalapposition.Fig. 3. Comparison of in stent neo-intima thickness of Cre8 and Vision/Multilink8 at 3-
month and 1-month follow-up, respectively.The present studywas based on the concept that strut uncoverage could
indicate a higher risk of stent thrombosis, particularly when this feature
includes many struts closed to each other, leading to the presence of
almost completely uncovered spots.
If conﬁrmed, the information gained by this study will help in the
future design of clinical trials to test the clinical outcome after Cre8
deployment in a regimen of reduced DAPT duration [22,23]. More
generally, the DEMONSTRATE trial would corroborate, with a solid
scientiﬁc basis, the recent reconsideration of DAPT duration proposed
withmodern DES (e.g. 3–6 months). Thus, the validity of this approach,
with a systematic OCTDES evaluation, preceding large clinical studies to
determine modern stent efﬁcacy/safety and DAPT duration, is unique
and should lead to further validation in larger cohort studies.5. Conclusions
In conclusion the DEMONSTRATE trial showed an almost complete
tissue coverage of the Cre8 DES after 3-months, comparable to that of
Vision/Multilink8 BMS at 1 month, and a sustained efﬁcacy in neo-
intimal suppression. Larger cohort studies with long term follow-up
arewarranted to test the effective clinical impact of this promising inno-
vative DES.Funding
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